P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.

Detalles Bibliográficos
Autores principales: Dickinson, Michael, Berkahn, Leanne, Trotman, Judith, Butler, Jason, Neeson, Paul, Bressel, Matthias, Minson, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431515/
http://dx.doi.org/10.1097/01.HS9.0000971160.69126.7e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431515/
http://dx.doi.org/10.1097/01.HS9.0000971160.69126.7e

Ejemplares similares